Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Bio-heart Biological Technology Co (HKSE:02185) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shanghai Bio-heart Biological Technology Co EBITDA Margin % Related Terms
Shanghai Bio-heart Biological Technology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Bio-heart Biological Technology Co EBITDA Margin % Chart
Shanghai Bio-heart Biological Technology Co Annual Data
HKSE:02185 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Shanghai Bio-heart Biological Technology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Bio-heart Biological Technology Co EBITDA Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Bio-heart Biological Technology Co (HKSE:02185) has a EBITDA Margin % of -219.76% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Bio-heart Biological Technology Co and its competitors. According to the industry distribution chart, Shanghai Bio-heart Biological Technology Co ranks #555 out of 942 companies in the Biotechnology industry, placing it in the top 58.9%.
Is Shanghai Bio-heart Biological Technology Co's EBITDA Margin % too high?
Shanghai Bio-heart Biological Technology Co's current EBITDA Margin % is -219.76%. Based on the distribution chart, Shanghai Bio-heart Biological Technology Co ranks #555 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shanghai Bio-heart Biological Technology Co has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Bio-heart Biological Technology Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Bio-heart Biological Technology Co ranks #555 out of 942 companies for EBITDA Margin %. This places Shanghai Bio-heart Biological Technology Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Bio-heart Biological Technology Co and its competitors. Shanghai Bio-heart Biological Technology Co's current EBITDA Margin % is -219.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Bio-heart Biological Technology Co stock overvalued right now?
Shanghai Bio-heart Biological Technology Co (HKSE:02185) has a current EBITDA Margin % of -219.76%. The current EBITDA Margin % is -219.76%. Shanghai Bio-heart Biological Technology Co's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shanghai Bio-heart Biological Technology Co (HKSE:02185), the current EBITDA Margin % is -219.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shanghai Bio-heart Biological Technology Co Ltd is engaged in the research and development of bioresorbable scaffold (BRS) products and the renal denervation (RDN) system. The company is a interventional cardiovascular device company in China, and locate in Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. Focused on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension. Currently, the portfolio has three product candidates in various stages of clinical development.
28GF Score
Get the complete analysis for HKSE:02185
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02185 has been successfully added to your 
